Condition
Precision Cell Immunotherapy
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Unknown4
Clinical Trials (4)
Showing 4 of 4 trials
NCT02873442Phase 1UnknownPrimary
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
NCT02873416Phase 1UnknownPrimary
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer
NCT02873520Phase 1UnknownPrimary
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
NCT02862561Phase 1UnknownPrimary
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Showing all 4 trials